|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2009-6-29
|
|
pubmed:abstractText |
The presence of aberrantly methylated SEPT9 DNA in plasma is highly correlated with the occurrence of colorectal cancer. We report the development of a new SEPT9 biomarker assay and its validation in case-control studies. The development of such a minimally invasive blood-based test may help to reduce the current gap in screening coverage.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1530-8561
|
|
pubmed:author |
pubmed-author:DayRobertR,
pubmed-author:DistlerJürgenJ,
pubmed-author:FleshnerPhillip RPR,
pubmed-author:GrützmannRobertR,
pubmed-author:HabermannJens KJK,
pubmed-author:Lofton-DayCatherineC,
pubmed-author:ModelFabianF,
pubmed-author:OubreBenton MBM,
pubmed-author:PilarskyChristianC,
pubmed-author:SchusterMatthiasM,
pubmed-author:SledziewskiAndrew ZAZ,
pubmed-author:SteigerKathryn VKV,
pubmed-author:TetznerReimoR,
pubmed-author:WeissGunterG,
pubmed-author:deVosTheoT
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1337-46
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.
|
|
pubmed:affiliation |
Epigenomics Inc., Seattle, WA 98101, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
